Enanta Pharmaceuticals: Q4 Earnings Insights

Shares of Enanta Pharmaceuticals ENTA were flat in after-market trading after the company reported Q4 results.

Quarterly Results

Earnings per share decreased 431.82% over the past year to ($1.46), which missed the estimate of ($0.95).

Revenue of $23,631,000 declined by 53.95% from the same period last year, which missed the estimate of $25,740,000.

Looking Ahead

Enanta Pharmaceuticals hasn't issued any earnings guidance for the time being.

Revenue guidance hasn't been issued by the company for now.

How To Listen To The Conference Call

Date: Nov 23, 2020

Time: 04:30 PM

ET Webcast URL: https://event.on24.com/eventRegistration/EventLobbyServlet?target=reg20.jsp&referrer=https%3A%2F%2Fwww.enanta.com%2F&eventid=2623162&sessionid=1&key=341D134C094DB86AD6D1C5731F999FD4&regTag=&sourcepage=register

Technicals

52-week high: $67.88

Company's 52-week low was at $38.40

Price action over last quarter: down 5.21%

Company Overview

Enanta Pharmaceuticals Inc is an American biotechnology company focused on research and development of molecule drugs to cure viral infections and liver diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.